津药药业(600488.SH)：子公司注射用甲泼尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书

Core Viewpoint - Tianjin Pharmaceutical Industry Co., Ltd. (津药药业) announced that its subsidiary, Tianjin Yaohe Pharmaceutical Co., Ltd., has received a registration certificate from the Ministry of Health of the Republic of Panama for its injectable Methylprednisolone Acetate, allowing production and sales in the Panamanian market [1] Group 1 - The drug Methylprednisolone Acetate is a corticosteroid used for anti-inflammatory treatment, immunosuppressive therapy, treatment of blood diseases, tumors, and shock [1] - The registration application was submitted in 2024, and the certificate was received in November 2025 [1] - According to IQVIA data, the global market sales for Methylprednisolone injectable products were $526 million in 2023 and are projected to be $521 million in 2024 [1] Group 2 - The registration of Methylprednisolone Acetate in Panama presents new opportunities for the company's formulation business and further supports its international strategic layout [1]